This site is intended for US healthcare professionals
Alkermes logo
Alkermes logo
Educational Resources
Resources Home
Congresses
Product Information
Our Pipeline
Knowledge Vault
Contact an MSL
Medical Information
Research & Medical Grants

Congresses

The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

This section includes selected Alkermes abstracts, posters or oral presentations, which have been accepted for congress presentations in the last 2 years. The content contained in this section is subject to congress copyright permissions.

Neuroscience Education Institute
November 7th – 10th 2024, Colorado Springs, CO
Explore materials from this congress
PLEASE NOTE: Materials will be available on a rolling basis after individual embargoes are lifted.
Bipolar Disorder
Schizophrenia
ENCORE POSTER
Long-Term Safety and Efficacy of Olanzapine and Samidorphan: Results of a 4-Year Open-Label Study
AUTHOR(S)

Jacob S. Ballon,1 René S. Kahn,2 Christina Arevalo,3 Martin Dunbar,3 David McDonnell,4 Christoph U. Correll5-7

View poster
Bipolar Disorder
Schizophrenia
Schizophrenia
ENCORE POSTER
Healthcare Resource Utilization 12 Months Following Initiation of Olanzapine/Samidorphan: Real-World Assessment of Patients With Schizophrenia
AUTHOR(S)

Andrew J. Cutler, MD,1,2 Hemangi R. Panchmatia, MSc,3 Alejandro G. Hughes, MPH,4 Michael J. Doane, PhD,3 Hara E. Oyedeji, CRNP, MS,5 Rakesh Jain, MD, MPH6

View poster
Schizophrenia
Bipolar Disorder
ENCORE POSTER
Healthcare Resource Utilization 12 Months Following Initiation of Olanzapine/Samidorphan: Real-World Assessment of Patients With Bipolar I Disorder
AUTHOR(S)

Rakesh Jain, MD, MPH,1 Hemangi R. Panchmatia, MSc,2 Alejandro G. Hughes, MPH,3 Michael J. Doane, PhD,2 Hara E. Oyedeji, CRNP, MS,4 Andrew J. Cutler, MD5,6

View poster
Bipolar Disorder
Schizophrenia
ENCORE POSTER
Baseline Severity of Illness and Response to Treatment With Aripiprazole Lauroxil Every 2 Months: A Post Hoc Analysis of Phase 3 ALPINE Clinical Trial Data
AUTHOR(S)

John M. Kane, MD1 ; Martin Dunbar, PhD2 ; and James A. McGrory, PhD2

View poster
Schizophrenia
Schizophrenia
ENCORE POSTER
Treatment Patterns and Healthcare Resource Utilization Following Initiation of Aripiprazole Lauroxil Using a 1-Day Initiation Regimen
AUTHOR(S)

Lauren N. Strand, PhD, MS1 ; Michael J. Doane, PhD1 ; James A. McGrory, PhD1 ; Alejandro G. Hughes, MPH2 ; John Lauriello, MD3

View poster
Schizophrenia
Schizophrenia
ENCORE POSTER
Clinical Characteristics, Treatment Patterns, and Healthcare Resource Utilization of Patients Prescribed Aripiprazole Lauroxil Versus Oral Aripiprazole: A Retrospective Claims-Based Study
AUTHOR(S)

John M. Kane, MD,1 Andrea B. Barthel, MS,2 Chenxue Liang,2 Zhengfan Wang,2 Elizabeth S. Nagelhout,2 Lauren N. Strand, PhD, MS,3 Michael J. Doane, PhD,3 Regina Grebla, PhD3

View poster
Schizophrenia
Narcolepsy
ENCORE POSTER
The Burden of Living With Narcolepsy: Patient Perspectives From In-Depth Qualitative Interviews
AUTHOR(S)

Michael J. Doane,1 Meaghan O’Connor,2 Miranda Lauher-Charest,2 Laura Tesler Waldman,2 Wilbur P. Williams, III1

View poster
Narcolepsy
Narcolepsy
ENCORE POSTER
Clinical, Economic, and Humanistic Burden Associated With Narcolepsy: Results From a Systematic Literature Review
AUTHOR(S)

Michael J. Doane,1 Miranda Lauher-Charest,2 Gia Huynh,2 Kristen McCausland2

View poster
Narcolepsy
Contact Us Terms of Use Privacy Policy www.alkermes.com

The product information provided on this site is intended only for healthcare professionals in the United States and is for informational purposes only. This site is designed to provide background and scientific findings concerning Alkermes products and areas of therapeutic interest. Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. There is no guarantee that the pipeline products or investigational uses will receive FDA approval. Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.

If you have a suspected Adverse Event or Product Complaint to report, please contact us by phone at 888-235-8008 or contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

Your use of this information is subject to the terms and conditions of our Privacy Policy.

© 2024 Alkermes, Inc. All rights reserved. MA-004230

Please review our Privacy Policy.

By using our website without changing your cookie settings you agree to our use of cookies as described in our Privacy Policy. Learn more.

Close
This site is intended for US healthcare professionals
Alkermes Logo
Educational Resources
Congresses
Product Information
Our Pipeline
Contact an MSL
Medical Information
Research & Medical Grants